olinvacimab + capecitabine

The combination of olinvacimab and capecitabine appears to be an investigational drug combination. **Olinvacimab** is a drug being developed by PharmAbcine and is described as their "lead asset" that will undergo an Investigator-Initiated Trial (IIT) in combination with capecitabine[3]. The search results do not provide detailed information about its mechanism of action or specific properties. **Capecitabine** is an established oral chemotherapy medication used in various cancer treatments. It is used alone or in combination for conditions such as Stage III colon cancer, spread rectal cancer, spread/unremovable colorectal cancer, metastatic breast cancer (often with docetaxel or alone), and combination treatments for esophageal, gastric, and gastroesophageal junction cancers, as well as preventing pancreatic cancer recurrence after surgery[2]. Capecitabine belongs to the antineoplastics group and works by interfering with cancer cell growth, leading to their destruction[2]. **Combination Use** The combination is in early investigational stages and was mentioned in Q4 2020 as soon to undergo an IIT[3]. No specific efficacy or safety results for this particular combination are provided in the search results.